The process of developing a non-medical (advanced allied health) botulinum toxin A prescribing and injecting model of care in a public rehabilitation setting

Aust Health Rev. 2013 Nov;37(5):624-31. doi: 10.1071/AH12008.

Abstract

Objective: The aim of this paper was to describe the process undertaken to develop a non-medical (advanced allied health extended role) botulinum toxin A prescription and injection project for adults with upper and lower limb spasticity secondary to an acquired brain injury. The hypertonicity clinic in the present study was located in a metropolitan public hospital in Queensland where multidisciplinary services are provided by a rehabilitation specialist and an advanced occupational therapist and physiotherapist.

Methods: The process of developing the model included establishing potential benefits for the role extension project and documentation of a project plan.

Results: Project outcomes included the development of a relevant governance structure, a research evidence-based project evaluation framework, a draft research ethics application, delineation of the key eligibility criteria and competencies required for physiotherapist and occupational therapist prescribers, and a final project report.

Conclusion: Non-medical prescribing has the potential to increase patient access to botulinum toxin A injection for the management of focal spasticity. A process that supports early patient engagement, extensive consultation with relevant stakeholders, a strong governance structure, a high-quality research project and a long lead time may maximise the potential for successful completion of advanced allied health role extension projects, including prescription and injection of botulinum toxin A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allied Health Personnel*
  • Botulinum Toxins, Type A / administration & dosage*
  • Hospitals, Public
  • Humans
  • Injections
  • Muscle Spasticity / drug therapy*
  • Neuromuscular Agents / administration & dosage*
  • Occupational Therapy
  • Physical Therapists
  • Program Development
  • Program Evaluation
  • Queensland
  • Role*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A